Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1968 1
1969 1
1973 2
1976 1
1977 1
1983 1
1985 1
1989 1
1998 1
2000 1
2003 2
2004 5
2005 2
2006 1
2007 3
2008 4
2009 5
2010 3
2011 3
2012 3
2013 6
2014 4
2015 3
2016 6
2017 12
2018 10
2019 9
2020 20
2021 22
2022 14
2023 21
2024 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.
Guirguis AA, Ofir-Rosenfeld Y, Knezevic K, Blackaby W, Hardick D, Chan YC, Motazedian A, Gillespie A, Vassiliadis D, Lam EYN, Tran K, Andrews B, Harbour ME, Vasiliauskaite L, Saunders CJ, Tsagkogeorga G, Azevedo A, Obacz J, Pilka ES, Carkill M, MacPherson L, Wainwright EN, Liddicoat B, Blyth BJ, Albertella MR, Rausch O, Dawson MA. Guirguis AA, et al. Cancer Discov. 2023 Oct 5;13(10):2228-2247. doi: 10.1158/2159-8290.CD-23-0007. Cancer Discov. 2023. PMID: 37548590
Small-molecule-induced polymerization triggers degradation of BCL6.
Słabicki M, Yoon H, Koeppel J, Nitsch L, Roy Burman SS, Di Genua C, Donovan KA, Sperling AS, Hunkeler M, Tsai JM, Sharma R, Guirguis A, Zou C, Chudasama P, Gasser JA, Miller PG, Scholl C, Fröhling S, Nowak RP, Fischer ES, Ebert BL. Słabicki M, et al. Among authors: guirguis a. Nature. 2020 Dec;588(7836):164-168. doi: 10.1038/s41586-020-2925-1. Epub 2020 Nov 18. Nature. 2020. PMID: 33208943 Free PMC article.
Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.
Schifano F, Catalani V, Sharif S, Napoletano F, Corkery JM, Arillotta D, Fergus S, Vento A, Guirguis A. Schifano F, et al. Among authors: guirguis a. Drugs. 2022 Apr;82(6):633-647. doi: 10.1007/s40265-022-01701-7. Epub 2022 Apr 2. Drugs. 2022. PMID: 35366192 Review.
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.
Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, Schifano F. Chiappini S, et al. Among authors: guirguis a. Pharmaceuticals (Basel). 2023 Jul 11;16(7):994. doi: 10.3390/ph16070994. Pharmaceuticals (Basel). 2023. PMID: 37513906 Free PMC article.
Non-genetic determinants of malignant clonal fitness at single-cell resolution.
Fennell KA, Vassiliadis D, Lam EYN, Martelotto LG, Balic JJ, Hollizeck S, Weber TS, Semple T, Wang Q, Miles DC, MacPherson L, Chan YC, Guirguis AA, Kats LM, Wong ES, Dawson SJ, Naik SH, Dawson MA. Fennell KA, et al. Among authors: guirguis aa. Nature. 2022 Jan;601(7891):125-131. doi: 10.1038/s41586-021-04206-7. Epub 2021 Dec 8. Nature. 2022. PMID: 34880496
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer.
Vergote I, Pérez-Fidalgo JA, Hamilton EP, Valabrega G, Van Gorp T, Sehouli J, Cibula D, Levy T, Welch S, Richardson DL, Guerra EM, Scambia G, Henry S, Wimberger P, Miller DS, Klat J, Martínez-Garcia J, Raspagliesi F, Pothuri B, Romero I, Bergamini A, Slomovitz B, Schochter F, Høgdall E, Fariñas-Madrid L, Monk BJ, Michel D, Kauffman MG, Shacham S, Mirza MR, Makker V; ENGOT-EN5/GOG-3055/SIENDO Investigators. Vergote I, et al. J Clin Oncol. 2023 Dec 10;41(35):5400-5410. doi: 10.1200/JCO.22.02906. Epub 2023 Sep 5. J Clin Oncol. 2023. PMID: 37669480 Clinical Trial.
Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death.
Garciaz S, Guirguis AA, Müller S, Brown FC, Chan YC, Motazedian A, Rowe CL, Kuzich JA, Chan KL, Tran K, Smith L, MacPherson L, Liddicoat B, Lam EYN, Cañeque T, Burr ML, Litalien V, Pomilio G, Poplineau M, Duprez E, Dawson SJ, Ramm G, Cox AG, Brown KK, Huang DCS, Wei AH, McArthur K, Rodriguez R, Dawson MA. Garciaz S, et al. Among authors: guirguis aa. Cancer Discov. 2022 Mar 1;12(3):774-791. doi: 10.1158/2159-8290.CD-21-0522. Cancer Discov. 2022. PMID: 34862195 Free PMC article.
170 results